Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

NCT02314143 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
48
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early due to slow enrollment and limited numbers of viable tissue samples.

Conditions

Interventions

Sponsor

GlaxoSmithKline